Abiraterone clinical trials
Also written JNJ-212082 and CB 7598.
Includes 127 studies of Abiraterone Acetate.
Related medicines add 3 studies
Counted the way a researcher would: Abiraterone with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses abiraterone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the abiraterone studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Apr 2011 · ZYTIGA · NDA 202379 (FDA, Drugs@FDA; as Abiraterone Acetate)
- European Union
- 5 Sept 2011 · Zytiga · EMEA/H/C/002321 (EMA; as Abiraterone Acetate)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
164 studies that test it; most in 2012 (16)
| Year | Studies |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 16 |
| 2013 | 13 |
| 2014 | 12 |
| 2015 | 5 |
| 2016 | 10 |
| 2017 | 9 |
| 2018 | 6 |
| 2019 | 9 |
| 2020 | 14 |
| 2021 | 11 |
| 2022 | 5 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 61 · Other 103
Janssen Research & Development, LLC (26) · Cougar Biotechnology, Inc. (9) · M.D. Anderson Cancer Center (6) · University of Washington (4) · Memorial Sloan Kettering Cancer Center (3) · UNICANCER (3) · Dana-Farber Cancer Institute (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3)
Often tested with
Tested in the same studies.
Prednisone (36) · Enzalutamide (18) · Apalutamide (16) · Niraparib (7) · Leuprolide (6) · Docetaxel (6) · Prednisolone (6) · Cabazitaxel (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 7 phase 3 studies under way
Abiraterone is the comparator. A study of two new drugs counts under both.
- 2Opevesostat · Merck Sharp & Dohme LLC · next primary completion May 2028
- 1Dezandrodeg · Celgene · next primary completion Sep 2027
- 1Xaluritamig · Amgen · next primary completion Jan 2029
- 1Cabozantinib · Exelixis
- 1Atezolizumab · Exelixis
- 1Darolutamide · ECOG-ACRIN Cancer Research Group · next primary completion Mar 2029
- 1Risvutatug rezetecan · GlaxoSmithKline · next primary completion Dec 2029
Reaching primary completion within a year · 11, 1 in phase 3
Studies that test abiraterone, phase 3 first.
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Nov 2026Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerPhase 2 · University of California, Davis
- Dec 2026Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II StudyPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Dec 2026Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)Phase 2 · SMED Clinical Research
- Dec 2026Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Jan 2027Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Feb 2027Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerPhase 2 · M.D. Anderson Cancer Center
- May 2027A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerPhase 1/2 · University of Michigan Rogel Cancer Center
- Jun 2027Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase 2 · University of British Columbia
- Aug 2027Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerPhase 2 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses abiraterone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 164
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)RecruitingPhase 1/2Novartis PharmaceuticalsNCT07190300Written as AbirateroneHow we know
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Abiraterone AcetateHow we know
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Written as abiraterone acetateHow we know
- Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate CancerRecruitingPhase 2University of NebraskaNCT07237269Written as AbirateroneHow we know
- A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPCRecruitingPhase 1/2Novartis PharmaceuticalsNCT07226986Written as AbirateroneHow we know
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingPhase 2Mayo ClinicNCT07650240Written as Abiraterone AcetateHow we know
- Abiraterone With Dalpiciclib in Salivary Gland CarcinomaRecruitingPhase 2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07815522Written as abiraterone combined with dalpiciclibHow we know
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Abiraterone Acetate 250mgHow we know
- Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)RecruitingPhase 2University Health Network, TorontoNCT05404139Written as AbirateroneHow we know
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingPhase 2Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicNCT07717268Written as Zytiga® (Abiraterone Acetate)How we know
- Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyRecruitingPhase 2University of WashingtonNCT04175431Written as Abiraterone AcetateHow we know
- SNV1521 in Participants With Advanced Solid TumorsRecruitingPhase 1Synnovation Therapeutics, Inc.NCT06220864Written as AbirateroneHow we know
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingPhase 2Sun Pharmaceutical Industries LimitedNCT05422911Written as Abiraterone acetateHow we know
- Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate CancerRecruitingPhase 2University of California, DavisNCT06173362Written as AbirateroneHow we know
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06616597Written as Abiraterone acetateHow we know
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Abiraterone AcetateHow we know
- Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)RecruitingPhase 2SMED Clinical ResearchNCT07299292Written as Abiraterone 250 mg with food + prednisoneHow we know
- Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerRecruitingPhase 2Martha MimsNCT03833921Written as Abiraterone AcetateHow we know
- Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer:a Phase II StudyRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07093866Written as Abiraterone + prednisoneHow we know
- Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)RecruitingPhase 4Deventer ZiekenhuisNCT07001709Written as Abiraterone Acetate Tablets 500 mgHow we know
See all 164 studies that test abiraterone →
Given beside what is tested · 120 — abiraterone is usual care or a partner of the new treatment
- Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1AmgenNCT04221542Written as AbirateroneHow we know
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Abiraterone acetate plus prednisone (AAP)How we know
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingPhase 1/2Merck Sharp & Dohme LLCNCT07908524Written as Abiraterone acetateHow we know
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationPhase 3ExelixisNCT07620574Written as AbirateroneHow we know
- A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate CancerRecruitingPhase 1Novartis PharmaceuticalsNCT07570979Written as AbirateroneHow we know
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingPhase 1/2DualityBio Inc.NCT05914116Written as AbirateroneHow we know
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingPhase 3AmgenNCT07213674Written as Abiraterone acetateHow we know
- AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingPhase 3AstraZenecaNCT07611110Written as AbirateroneHow we know
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingPhase 3AstraZenecaNCT07711002Written as AbirateroneHow we know
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingPhase 3AstraZenecaNCT06952803Written as Abiraterone + Prednisolone/PrednisoneHow we know
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06863272Written as AbirateroneHow we know
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingPhase 3SWOG Cancer Research NetworkNCT03678025Written as AbirateroneHow we know
- Study of XNW5004 Tablets in Advanced Prostate CancerNot yet recruitingPhase 2Evopoint Biosciences Inc.NCT07730580Written as XNW5004 1200 mg BID in Combination with Abiraterone plus PrednisoneHow we know
- A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingPhase 2/3Sichuan Baili Pharmaceutical Co., Ltd.NCT07641855Written as AbirateroneHow we know
- The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)RecruitingPhase 3Telix Pharmaceuticals (Innovations) Pty LimitedNCT06520345Written as AbirateroneHow we know
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA ResponseRecruitingPhase 3Canadian Cancer Trials GroupNCT06592924Written as AbirateroneHow we know
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Abiraterone acetate (Zytiga®) 250 mg or 500 mg tabletsHow we know
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06457919Written as abiraterone acetate with prednisoneHow we know
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Written as Abiraterone AcetateHow we know
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07198633Written as abiraterone acetateHow we know
Showing 20 of 120.
As the comparator · 22 — what is tested is compared with abiraterone
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136624Written as Abiraterone acetateHow we know
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150Written as AbirateroneHow we know
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136650Written as Abiraterone acetateHow we know
- A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]RecruitingPhase 3GlaxoSmithKlineNCT07802704Written as AbirateroneHow we know
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Abiraterone AcetateHow we know
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07005154Written as abiraterone acetateHow we know
- Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05942001Written as Abiraterone acetate tabletsHow we know
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialRecruitingPhase 2Mayo ClinicNCT06378866Written as AbirateroneHow we know
- Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate CancerNot yet recruitingNot applicableChanghai HospitalNCT05707468Written as ADT combined with abirateroneHow we know
- A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 3CelgeneNCT06764485Written as AbirateroneHow we know
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingPhase 2Rutgers, The State University of New JerseyNCT02949284Written as Abiraterone AcetateHow we know
- Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)Active, not recruitingPhase 3AmgenNCT06691984Written as AbirateroneHow we know
- A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 2R-Pharm International, LLCNCT07553988Written as AbirateroneHow we know
- Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingPhase 4AstraZenecaNCT05457257Written as abiraterone acetateHow we know
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedPhase 2MacroGenicsNCT05551117Written as AbirateroneHow we know
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingPhase 3ExelixisNCT04446117Written as Abiraterone AcetateHow we know
- Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT03834519Written as Abiraterone acetateHow we know
- Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting AgentTerminatedPhase 3Veru Inc.NCT04844749Written as Enzalutamide, AbirateroneHow we know
- TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerCompletedPhase 3Tavanta TherapeuticsNCT04887506Written as ZytigaHow we know
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedPhase 3AstraZenecaNCT02987543Written as abiraterone acetateHow we know
Showing 20 of 22.
Codes
What other systems call abiraterone · ClinicalTrials.gg INT003801
- MeSH (NLM) C089740abirateroneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) G819A456D0ABIRATERONEConfirmed FDA, NLM, Wikidata
- RxNorm 1100072Confirmed FDA, Wikidata
- Wikidata Q321431abirateroneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77333AbirateroneOne source FDA
- DrugBank DB05812One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C089740 | abiraterone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | G819A456D0 | ABIRATERONE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1100072 | — | Confirmed FDA, Wikidata |
| Wikidata | Q321431 | abiraterone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77333 | Abiraterone | One source FDA |
| DrugBank | DB05812 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.